Polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT).
|NCPE Assessment Process||Complete|
|Rapid Review commissioned||03/12/2019|
|Rapid Review completed||27/01/2020|
|Rapid Review Outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of polatuzumab vedotin (Polivy®) compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||26/02/2020|
|Pre-submission consultation with Applicant||31/03/2020|
|Full submission received from Applicant||10/07/2020|
|Preliminary review sent to Applicant||27/10/2020|
|NCPE assessment re-commenced||25/11/2020|
|Factual accuracy check sent to Applicant||26/01/2021|
|NCPE assessment re-commenced||02/02/2021|
|NCPE assessment completed||16/02/2021|
|NCPE assessment outcome||The NCPE recommends that polatuzumab vedotin (Polivy®) be considered for reimbursement if cost effectiveness can be improved relative to existing treatments.*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.